Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hip implant showdown: which stem saves more bone?

NCT ID NCT01285843

Knowledge-focused Sponsor: Medacta International SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 40 people who had a total hip replacement through a small incision in the front of the hip. Researchers compared two types of metal stems (AMIStem and Quadra) to see how bone density around the implant changed one year after surgery. The goal was to find out if one stem leads to better bone preservation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help surgeons choose which implant type leads to better bone preservation after hip replacement.
What could go wrong
This is a small, completed observational study with only 40 participants, so results may not apply to all patients. It does not test a new treatment or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Start date

Sep 2010

Finished

Sep 2012

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery. * Patients presenting with disease that meets the indications for use for Medacta implants defined by this study (on-label use (enclosure 2)). * Patients must be willing to comply with the pre and post-operative evaluation schedule. * Patients with only one lower limb arthroplasty Exclusion Criteria: * Patient with metabolic bone diseases, use of steroids or other drugs affecting bone metabolism * Patients with osteoporosis (pre-op T-score \< -2,5) * Patients with significant comorbidities * Patients with both hip and knee arthroplasty * Patients with restricted mobility * Patient with severe hip contracture * Those with one or more medical conditions identified as a contraindication defined by the labeling on any Medacta implants used in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease avascular necrosis developmental dysplasia of the hip femoral neck fracture Hip Dislocation, Congenital hip fracture osteoarthritis osteonecrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis Avascular necrosis Congenital hip dysplasia Fracture of the femoral neck or head Osteoarthritis

Contacts and locations

Locations

  • St. Elisabeth Dillingen

    Dillingen an der Donau, Bavaria, 89407, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.